Red List

RAREUltragenyx Pharmaceutical Inc.

Healthcare · Biotechnology · mid-cap ($2.6B)
-36.5%
from rolling 252-day high of $39.89 set 2025-12-08 · 255d ago
Current
$25.32
Decline depth
-36.5%
Decline σ
4.5σ
TFC
5/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since tracking began

$RARE has been tracked since 2026-03-01. It was down 47.1% from its 52-week high then — now down -36.5%.

It has clawed back 6.4 percentage points off that level. It bottomed 57.5% below that high along the way.

Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

RARE qualifies for the Red List on decline depth.

Decline depth
-36.5%
From rolling 252-day high of $39.89, 255d ago. Past the 30% Amber threshold.
Time-frame continuity
5/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Full bearish continuity — every time frame is broken.
Decline sigma
4.5σ
Drop from local high over the last 5 bars, expressed in units of the stock's typical daily volatility (2.71% per day). Past the ≥4σ Watch threshold.

The structural read

What price action says about RARE.

RARE qualifies for the Red List on decline depth — down -36.5% from its rolling 252-day high. Past 30% with the high set inside the last four months — the recency clause that often precedes further breakdown.

Cross-confirmation: also showing 5/5 bearish time frames.

Cross-confirmation: decline sigma also reads 4.5σ over 5 bars.

Upstream TFC read: weak alignment, current phase daily. Last bar types — daily 3 (red), weekly 3 (red), monthly 2D (green).

Earnings on file: 2026-05-05. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about RARE

What people ask.

Why is RARE on Broken Stocks?

RARE qualifies for the Red List on decline depth. It is down -36.5% from its rolling 252-day high of $39.89, set on 2025-12-08 — 255d ago.

Is RARE a falling knife?

Not by the strict technical definition. RARE is down -36.5% from its 52-week high, but that high was set 255d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. RARE is still on the Red List for decline depth, but the freshness component of a falling knife is missing.

Is RARE a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is RARE trading inside its 52-week range?

At $25.32, RARE sits 32.5% of the way from its 52-week low ($18.29) to its 52-week high ($39.89). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has RARE been declining?

The current 36.5% decline accrued over 255d, which annualizes to roughly -52.2% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does RARE compare to its sector?

There are 143 other Healthcare tickers on Broken Stocks: 69 Red, 35 Amber, 39 Watch, with 50 showing recovering structural signals. Median sector decline is -36.1% — RARE's decline is deeper than the sector median.

Does RARE's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-05) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.